{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:48:51Z","timestamp":1791114531564,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.jaad.2009.12.052","type":"journal-article","created":{"date-parts":[[2010,10,4]],"date-time":"2010-10-04T05:24:00Z","timestamp":1286169840000},"page":"975-983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma"],"prefix":"10.1016","volume":"63","author":[{"given":"Youn H.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Kuzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Pinter-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H.","family":"Rook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2009.12.052_bib1","first-page":"276","article-title":"Mycosis fungoides and the S\u00e9zary syndrome","volume":"26","author":"Kim","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jaad.2009.12.052_bib2","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and S\u00e9zary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2009.12.052_bib3","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1056\/NEJMra032810","article-title":"The pathogenesis of mycosis fungoides","volume":"350","author":"Girardi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2009.12.052_bib4","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI24826","article-title":"Immunopathogenesis and therapy of cutaneous T cell lymphoma","volume":"115","author":"Kim","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2009.12.052_bib5","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1182\/blood.V99.8.2929","article-title":"The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells","volume":"99","author":"Berger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2009.12.052_bib6","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1182\/blood-2004-06-2181","article-title":"Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells","volume":"105","author":"Berger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2009.12.052_bib7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0889-8588(18)30054-6","article-title":"The immunopathogenesis of cutaneous T-cell lymphoma","volume":"9","author":"Rook","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jaad.2009.12.052_bib8","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/blood-2003-04-1044","article-title":"Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma","volume":"102","author":"Yawalkar","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2009.12.052_bib9","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1182\/blood-2002-01-0231","article-title":"S\u00e9zary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines","volume":"100","author":"Wysocka","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2009.12.052_bib10","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2009.12.052_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2009.12.052_bib12","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2009.12.052_bib13","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaad.2006.06.038","article-title":"A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides","volume":"55","author":"Duvic","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.052_bib14","first-page":"3","article-title":"Current treatment of cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2001","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2009.12.052_bib15","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0889-8588(18)30060-1","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Olsen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jaad.2009.12.052_bib16","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood-2002-08-2455","article-title":"Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate\u2013pulsed dendritic cells","volume":"102","author":"Maier","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2009.12.052_bib17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd2059","article-title":"Therapeutic potential of Toll-like receptor 9 activation","volume":"5","author":"Krieg","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaad.2009.12.052_bib18","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1172\/JCI31414","article-title":"Development of TLR9 agonists for cancer therapy","volume":"117","author":"Krieg","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2009.12.052_bib19","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1200\/JCO.2006.07.9129","article-title":"Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma","volume":"24","author":"Pashenkov","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2009.12.052_bib20","first-page":"416","article-title":"Phase Ib trial of a targeted TLR9 CpG immunomodulator (CPG 7909) in advanced renal cell carcinoma (RCC)","volume":"23","author":"Thompson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2009.12.052_bib21","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.cji.0000211304.60126.8f","article-title":"Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma","volume":"29","author":"Link","year":"2006","journal-title":"J Immunother"},{"key":"10.1016\/j.jaad.2009.12.052_bib22","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/00002371-200411000-00006","article-title":"Al Adhami MJ, Davis HL. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist","volume":"27","author":"Krieg","year":"2004","journal-title":"J Immunother"},{"key":"10.1016\/j.jaad.2009.12.052_bib23","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1182\/blood-2004-03-1190","article-title":"Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15","volume":"104","author":"Wysocka","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2009.12.052_bib24","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1158\/1078-0432.CCR-07-0815","article-title":"Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma","volume":"13","author":"Leonard","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"10.1016\/j.jaad.2009.12.052_bib25","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/1097-0142(19860415)57:8+<1689::AID-CNCR2820571311>3.0.CO;2-M","article-title":"The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas","volume":"57","author":"Bunn","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2009.12.052_bib26","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-121-8-199410150-00007","article-title":"Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the S\u00e9zary syndrome)","volume":"121","author":"Bunn","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2009.12.052_bib27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1172\/JCI23373","article-title":"Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909","volume":"115","author":"Speiser","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2009.12.052_bib28","doi-asserted-by":"crossref","unstructured":"Ai WYZ, Kim Y, Hoppe RT, Shah S, Horning SJ, Tibshirani R, et\u00a0al. Preliminary report on a phase I\/II study of intratumoral injection of PF-3512676 (CpG 7909), a TLR9 agonist, combined with radiation in recurrent low-grade lymphomas [abstract]. Presented at the American Society of Hematology 48th Annual Meeting and Exposition; December 9-12, 2006; Orlando, FL.","DOI":"10.1182\/blood.V108.11.2716.2716"},{"issue":"Suppl","key":"10.1016\/j.jaad.2009.12.052_bib29","first-page":"S43","article-title":"Novel in situ vaccination with intratumoral injection of CpG 7909, a TLR 9 agonist, combined with radiation in mycosis fungoides and primary cutaneous B-cell lymphoma","volume":"127","author":"Morales","year":"2007","journal-title":"J Invest Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962210000083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962210000083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:20:08Z","timestamp":1759270808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962210000083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0190962210000083"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2009.12.052","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2009.12.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}